TY  - JOUR
T1  - Β-blocker therapy and depression
AU  - Terao T
Y1  - 2002/10/16
N1  - 10.1001/jama.288.15.1845
JO  - JAMA
SP  - 1845
EP  - 1846
VL  - 288
IS  - 15
N2  - 
First, in addition to varying degrees of lipid solubility and generation,
there are other pharmacological differences among β-blockers. Several β-blockers,
such as pindolol, have antagonistic activity at somatodendritic 5-HT1A autoreceptors, and thereby increase serotonin release.2 This
action may lead to an improvement in depression. Räsänen et al3 reported that treatment with pindolol was associated
with a slightly but significantly lower rate of antidepressant use, suggesting
that pindolol may have some beneficial effects on mood. Although Ko et al
used a random-effects model to account for heterogeneity between studies,
they should have considered the additional heterogeneity associated with different β-blockers.

SN  - 0098-7484
M3  - doi: 10.1001/jama.288.15.1845
UR  - http://dx.doi.org/10.1001/jama.288.15.1845
ER  -